Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autologous bone Clear all
Completed Phase 1 Interventional

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

NCT02906371
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Childhood
Interventions
Tocilizumab, CART 19
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 24 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

NCT00058305
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions
bryostatin 1, vincristine sulfate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 23, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

NCT06207799
View directory record Official record
Conditions
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
Interventions
Elranatamab, Lenalidomide, Plerixafor, Melphalan, Busulfan, G-CSF, Stem cell transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

NCT04975698
View directory record Official record
Conditions
HIV Associated Lymphoma
Interventions
HST-NEETs, Bone Marrow Transplant
Biological
Lead sponsor
Catherine Bollard
NIH
Eligibility
15 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Duarte, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Rejuvenation of Premature Ovarian Failure With Stem Cells

NCT02696889
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Low Ovarian Reserve, Premature Ovarian Failure
Interventions
ROSE-1 Protocol
Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01936090
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Total-Body Irradiation, Melphalan, Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 23, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

NCT00275262
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Sep 23, 2026, 10:03 PM EDT
Withdrawn Not applicable Interventional

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

NCT01795430
View directory record Official record
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Sep 23, 2026, 10:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

NCT00753220
View directory record Official record
Conditions
Prostate Cancer
Interventions
VDC2008, Cyclophosphamide
Biological · Drug
Lead sponsor
Bostwick Laboratories
Industry
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 23, 2026, 10:03 PM EDT
Active, not recruiting Phase 1 Interventional

Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy

NCT01736059
View directory record Official record
Conditions
Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
Interventions
CD34+ bone marrow stem cells intravitreal
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00002805
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma

NCT01639612
View directory record Official record
Conditions
Grade IV Malignant Glioma
Interventions
ALD-451
Biological
Lead sponsor
Henry Friedman
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 23, 2026, 10:03 PM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

NCT06205342
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Mesenchymal Stem Cells, Other: Placebo
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 23, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

NCT00303719
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine, mycophenolate mofetil, stem cell transplantation, total body irradiation, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

NCT01916577
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Pulmonary Fibrosis
Interventions
Plerixafor mobilization of autologous CD117 stem cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 23, 2026, 10:03 PM EDT
Not listed Phase 2 Interventional

Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors

NCT00025324
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous and Allogeneic Transplant for Relapsed Lymphoma

NCT00802113
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkins Disease
Interventions
Fludarabine, Busulfan, Anti-Thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells

NCT01575470
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
autologous bone marrow mononuclear cells
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1Phase 2 Interventional

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

NCT00003954
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
melphalan, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, total-body irradiation, cyclosporine, mycophenolate mofetil, therapeutic allogeneic lymphocytes
Drug · Procedure · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Duarte, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Unrelated Donor Stem Cell Transplantation

NCT01364363
View directory record Official record
Conditions
Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Chronic Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Large Granulocytic Leukemia
Interventions
Allogeneic transplantation
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

NCT00002600
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 23, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

NCT00002592
View directory record Official record
Conditions
Leukemia
Interventions
c-myb antisense oligonucleotide G4460, filgrastim, busulfan, cyclophosphamide, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 23, 2026, 10:03 PM EDT
Withdrawn Phase 1 Interventional

Stem Cell Therapy as Adjunct to Revascularization

NCT00463853
View directory record Official record
Conditions
Coronary Arteriosclerosis, Coronary Artery Bypass Graft, Myocardial Revascularization
Interventions
Autologous stem cell therapy, CABG, CMRI
Procedure · Radiation
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 23, 2026, 10:03 PM EDT